Altera™ Comprehensive Genomic Profiling

Altera™ uses a combined whole-exome and whole-transcriptome sequencing approach, delivering a deeper understanding of each cancer’s unique genomic signature. It identifies clinically relevant biomarkers that can help guide patient management, from selecting targeted therapies and immunotherapies to matching patients with clinical trials.

When used alongside Signatera™ for recurrence monitoring, Altera™ helps maximize patient insights while conserving tissue for comprehensive, actionable results.

Biomarkers, treatments, clinical trial eligibility:

Comprehensive patient insights all in one place.

Altera™ empowers personalized therapy selection by identifying treatments most likely to benefit patients based on their tumor biomarkers and cancer type. The comprehensive report covers both well-established cancer driver genes and less common but actionable biomarkers, giving clinicians deeper insights to guide informed treatment decisions.

Oncologist discussing genomic profiling insights with a patient

Whole-exome DNA
Sequencing (WES)

Comprehensive genomic profiling across ~20,000 genes to identify genomic alterations, including SNVs, Indels, CNAs, & select gene rearrangements associated with targeted therapy options, immunotherapy response, resistance mechanisms, and clinical trial eligibility. The test also evaluates microsatellite instability (MSI) and tumor mutational burden (TMB) to provide a complete picture of potential immunotherapy opportunities.

Whole-transcriptome RNA Sequencing (WTS)

WTS expands analysis beyond the exome to capture structural rearrangements, clinically significant transcripts (AR-V7 & EGFR vIII), MET exon 14 skipping events, and fusions (e.g., NTRK 1/2/3), revealing novel drivers and emerging biomarkers often missed by conventional panels.

IHC

Altera™ automatically includes PD-L1 (22C3) and HER2 assessment by IHC, providing a more comprehensive profile to help inform personalized treatment strategies.

One tumour sample – two tests

With one tumour sample, you can order Altera™ to guide therapy selection and Signatera™ to monitor treatment response and disease recurrence. Enjoy the benefits of:

Start patient form

Tissue preservation
Streamlined ordering for both tests in a single submission
Enablement of long-term monitoring
Simpler logistics for patients
Truly personalised care for your oncology patients

Altera™ Comprehensive Genomic Profiling

Comprehensive patient insights all in one place.

Whole-exome DNASequencing (WES)

Whole-transcriptome RNA Sequencing (WTS)

IHC

One tumour sample – two tests

Useful Links

Whole-exome DNA
Sequencing (WES)